CORFLOW-THERAPEUTICS-AG
CorFlow Therapeutics AG (www.corflow-therapeutics.ch ) today announced that the company will present fundamental new insights into the coronary microcirculation during the annual meeting of the American College of Cardiology (ACC) in Orlando, FL, March 10-12, 2018.
CorFlow has since its foundation in June 2016 worked to document that the Controlled Flow Infusion (CoFITM ) technology is able to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time. Microvascular obstruction (MVO) affects more than half of the acute heart attack patients and is an independent predictor for complications including heart failure which constitutes a high cost burden for the world-wide health care system. To address this large unmet medical need in interventional cardiology, CorFlow has developed an in-vivo model which reproducibly creates MVO in an occlusion-reperfusion model with very low complication rates. Using this in-vivo model, the CoFITM technology was used to measure real-time dynamic microvascular resistance (dMVR) in the coronary circulation and these dMVR values were correlated to post-procedure contrast enhanced magnetic resonance imaging (MRI) and histology. A correlation between the procedural CoFITM dMVR values and post-procedural MRI will enable treatment of MVO before the patients leave the cathlab and potentially reduce the complication rates for severe heart attack patients.
In a comment, Dr. Renu Virmani, an internationally renowned cardiovascular pathologist and co-author of the histology poster, stated: "These findings suggest that the fundamental effects of a human heart attack have to be reconsidered. Our findings show that MVO in acute heart attacks can be created without the presence of thrombi. The results furthermore show that minute reductions in coronary volume flow causes an exponential collapse of the coronary microcirculation and that epicardial revascularization alone is not sufficient to open the collapsed coronary microcirculation. If these findings hold true in our upcoming investigations, we will have to fundamentally rethink the comprehensive treatment of an acute heart attack with attention to the microvasculature as well as the major epicardial vessels."
Jon H. Hoem, CorFlow's CEO and co-Founder, commented: "We are very pleased that our in-vivo results have been accepted for publication during the important ACC conference and look forward to discuss these results with cardiologists attending the conference."
The data from the CorFlow non-clinical trials will be used in the upcoming submissions for the CorFlow MOCA I (M VO with C oFI™ System A ssessment I) First-in-Man clinical trial.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180222005588/en/
Contact:
CorFlow Therapeutics AG
Jon H. Hoem, +41 79 606 2 902
jhoem@corflow-therapeutics.ch
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-HTEC/G2-RISK28.3.2024 17:03:32 CET | Press release
Faster Recoveries, Improved Security: HTEC and G2 Risk Solutions Join Forces to Advance Bankruptcy Management
YCVB28.3.2024 16:01:31 CET | Press release
The reopening of the Yokohama Museum of Art adds another innovative and distinctive venue for events in Yokohama
CA-LAMBDATEST28.3.2024 16:01:31 CET | Press release
LambdaTest Launches The Phoenix Project, an Employee Resource Group for Women
YCVB28.3.2024 16:01:31 CET | Press release
Eight new sustainability-themed experiences—exclusive to Yokohama—for convention participants
RI-NORDSON-EFD28.3.2024 15:01:30 CET | Press release
Nordson EFD Releases New 3-Axis Automated Fluid Dispensing Systems
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom